Search bioRxivSearch

Biology subjects

Sleigh, J. N.

Publications and source records attributed to Sleigh, J. N..

2 recordsLinked to original sources

ALS mice carrying pathological mutant TDP-43, but not mutant FUS, display axonal transport defects in vivo

Amyotrophic lateral sclerosis (ALS) is a fatal, progressive neurodegenerative disease resulting from a complex interplay between genetics and environment. Impairments in the basic neuronal process of axonal transport have been identified in several ALS models. However, in vivo evidence of early/pre-symptomatic deficiencies in neuronal cargo trafficking remains limited, thus the pathogenic importance of axonal transport to the ALS disease spectrum remains to be fully resolved. We therefore analysed the in vivo dynamics of retrogradely transported, neurotrophin-containing signalling endosomes in motor neuron axons of two new mouse models of ALS that have mutations in different RNA processing genes (Tardbp and Fus). TDP-43M337V mice, which show neuromuscular pathology but no overt motor neuron loss, displayed in vivo perturbations in axonal transport that manifested between 1.5 and 3 months and preceded motor symptom onset. In contrast, signalling endosome transport remained largely unaffected in mutant Fus{Delta}14/+ mice, despite 20% motor neuron loss. These findings indicate that deficiencies in retrograde neurotrophin signalling and axonal transport are not common to all ALS-linked genes, and that there are inherent and mechanistic distinctions in the pathogenesis of ALS caused by mutations in different RNA processing genes.

neuroscience

Neuropilin 1 sequestration by neuropathogenic mutant glycyl-tRNA synthetase is permissive to vascular development and homeostasis

It remains a mystery how dominantly inherited mutations in the housekeeping gene GARS, which encodes glycyl-tRNA synthetase (GlyRS), mediate selective peripheral nerve toxicity resulting in the currently incurable Charcot-Marie-Tooth disease type 2D (CMT2D). A recent study identified the transmembrane receptor protein neuropilin 1 (Nrp1) as a substrate for aberrant extracellular binding of mutant GlyRS. Formation of the Nrp1/mutant GlyRS complex antagonises the interaction of Nrp1 with one of its main natural ligands, vascular endothelial growth factor-A (VEGF-A), contributing to neurodegeneration. Reduced binding of Nrp1 to VEGF-A is known to disrupt blood vessel development and growth. We therefore analysed capillary architecture at early and later symptomatic time points in CMT2D mouse muscles, retina, and sciatic nerve, as well as in embryonic hindbrain. Assessing capillary diameter, density, and branching, we observed no differences between wild-type and mutant animals from embryonic development to three months, spanning the duration over which numerous sensory and neuromuscular phenotypes manifest. This work indicates that mutant GlyRS-mediated disruption of Nrp1/VEGF-A signalling is permissive to capillary maturation and maintenance in CMT2D mice.\n\nSummary StatementAlthough the multi-functional neuropilin 1/VEGF-A signalling pathway is impaired by dominant pathogenic GlyRS variants, the vascular system remains unperturbed in Gars mutant mice.

neuroscience